Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 8/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 10/20 | 0.42 |
| ▸ | DRD2 | P14416 | 9/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6218530 | 0.86 | HTR2A (0.51) | PARP1HTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL9366133 | 0.85 | HTR2A (0.60) | HTR1AHTR2ADRD2KCNH2HTR7 | |
| SCHEMBL6219855 | 0.84 | HTR2A (0.51) | PARP1HTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL27613982 | 0.84 | HTR1A (0.42) | PARP1HTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL6219645 | 0.83 | HTR2A (0.56) | HTR1AHTR2ADRD2 | |
| SCHEMBL6220416 | 0.81 | DRD2 (0.47) | PARP1HTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL6219285 | 0.79 | DRD2 (0.47) | PARP1HTR1ASLC6A4HTR2ADRD2 | |
| SCHEMBL6219433 | 0.77 | HTR1A (0.47) | PARP1HTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL6218716 | 0.77 | HTR1A (0.47) | PARP1HTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL9778374 | 0.76 | ABCB1 (0.60) | PARP1HTR1AHTR2ADRD2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1701072-A | Heterocyclic substituted piperazines for the treatment of schizophrenia | WARNER LAMBERT CO (US) | 2005-11-23 | — | — | CN | claimed |
| EP-1546143-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | ANDREANA TONJA LYNN (US) | 2004-07-15 | — | — | US | claimed |
| WO-2004026864-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-01 | — | — | WO | claimed |
| CN-1701072-A | Heterocyclic substituted piperazines for the treatment of schizophrenia | WARNER LAMBERT CO (US) | 2005-11-23 | — | — | CN | disclosed |
| EP-1546143-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | ANDREANA TONJA LYNN (US) | 2004-07-15 | — | — | US | disclosed |
| WO-2004026864-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINES FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | CNR1, DRD2, CNR2 | PARP1 3011/4885HTR1A 17/4885HTR1D 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.